Valuation Abbott Laboratories Bulgaria S.E.
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Bulgaria S.E.
26/05/2026
|
5-day change | 1st Jan Change | ||
| 74.08 EUR | +1.93% |
|
-.--% | -30.19% |
| 04/09 | US companies face rise in cyber attacks | RE |
| 01/09 | Mead Johnson wins US federal bellwether trial over preterm infant formula Enfamil | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,41,365 | 1,91,427 | 1,91,088 | 1,96,184 | 2,17,859 | 1,87,452 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -13.96% | - | - |
| Enterprise Value (EV) 1 | 2,49,166 | 1,98,318 | 1,98,871 | 2,02,693 | 2,22,266 | 2,11,391 | 2,08,410 | 2,04,719 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -4.89% | -1.41% | -1.77% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 31.1x | 23.9x | 21.4x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.91x | 3.75x | 3.56x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -4.95x | 0.8x | 1.8x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.73x | 3.43x | 3.21x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.2x | 3.81x | 3.5x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16.1x | 14.3x | 12.8x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 18x | 16x | 14.3x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26.7x | 22.3x | 20x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.75% | 4.49% | 4.99% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.37% | 2.53% | 2.67% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.486 | 4.524 | 5.074 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.6% | 57.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,302 | 54,646 | 58,409 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,090 | 14,598 | 16,020 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,313 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,232 | 7,924 | 8,850 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 108.33 | 108.33 | 108.33 |
| Nbr of stocks (in thousands) | 17,14,968 | 17,43,574 | 17,36,059 | 17,34,455 | 17,38,834 | 17,30,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.08x | 4.2x | 16.15x | 2.37% | 19TCr | |
| 19.92x | 3.63x | 12.95x | 3.01% | 12TCr | |
| 18.12x | 0.21x | 13.19x | 0.72% | 6.32TCr | |
| 29.59x | 7.29x | 18.82x | 1.35% | 5.17TCr | |
| 35.6x | 3.43x | 11.76x | 2.12% | 5.03TCr | |
| 35.23x | 6.2x | 19.45x | -.--% | 3.32TCr | |
| 47.24x | 1.35x | 12.52x | 0.2% | 3.21TCr | |
| 39.65x | 6.94x | 24.91x | 0.27% | 2.39TCr | |
| 18.12x | 2.89x | 10.23x | 1.53% | 2.3TCr | |
| Average | 30.51x | 4.02x | 15.55x | 1.29% | 6.5TCr | |
| Weighted average by Cap. | 28.60x | 3.88x | 15.15x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
